Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06663787 · ClinicalTrials.gov registry record
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR)
A clinical trial of Breast Cancer Metastatic and HER2 + Breast Cancer, sponsored by Nagoya City University.
- Active
- Registry status
- 50
- Enrollment target
- 4
- Study locations
NCT06663787 is a study of Breast Cancer Metastatic and HER2 + Breast Cancer that is active but no longer recruiting, run by Nagoya City University. The registered enrollment target is 50 participants, below the 89-participant average among 17 other Breast Cancer Metastatic trials with a reported enrollment target (44% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06663787, a study of Breast Cancer Metastatic and HER2 + Breast Cancer, is active but no longer recruiting, sponsored by Nagoya City University.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 4
- Study locations
Study Summary
Anti-HER2 therapy, such as trastuzumab and pertuzumab, has significantly improved long-term survival in HER2-positive breast cancer. The updated data of the CLEOPATRA trial showed significant Kaplan-Meier curves, suggesting the potential for a cure. However, the efficacy of maintenance therapy in long-term responders remains unexplored. This study will assess MRD in unresectable HER2-positive breast cancer cases with long-term response using the Signatera™ ctDNA assay, which could contribute to future treatment strategy development.
Conditions Studied
Interventions
- DRUG Trastuzumab (Herceptin)
- DIAGNOSTIC_TEST SIgnatera
Study Locations (4)
Aichi-ken
- Aichi Cancer Center - Nagoya
- Nagoya City University - Nagoya
Texas
- Natera - San Carlos
Tokyo
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research - Tokyo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06663787
The ClinicalTrials.gov registry entry for NCT06663787 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 17 other Breast Cancer Metastatic trials with a reported enrollment target (44% lower). The listed sponsor is Nagoya City University, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer Metastatic appearing as the primary indexed condition, and to 2 interventions - of which Trastuzumab (Herceptin) is the first listed.
NCT06663787 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Aichi-ken, Texas, Tokyo.
Frequently Asked Questions
What is clinical trial NCT06663787 about?
NCT06663787 is a clinical study titled "Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR)". Anti-HER2 therapy, such as trastuzumab and pertuzumab, has significantly improved long-term survival in HER2-positive breast cancer. The updated data of the CLEOPATRA trial showed significant Kaplan-Meier curves, suggesting the potential for a cure. However, the efficacy of maintenance therapy in lo...
What is the current status of trial NCT06663787?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2024-04-01. Estimated completion is 2025-12-31.
What conditions does trial NCT06663787 study?
This clinical trial studies the following conditions: Breast Cancer Metastatic, HER2 + Breast Cancer.
What interventions are being tested in trial NCT06663787?
The interventions under investigation include: Trastuzumab (Herceptin) (DRUG), SIgnatera (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06663787?
This trial is sponsored by Nagoya City University, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06663787 being conducted?
This trial has 4 study locations across Texas, Aichi-ken, Tokyo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
RECRUITING · Phase 2
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
RECRUITING · NA
-
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
RECRUITING · Phase 1
-
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.